195 related articles for article (PubMed ID: 28716757)
1. Saturated phosphatidylcholine as matrix former for oral extended release dosage forms.
Kolbina M; Bodmeier R; Körber M
Eur J Pharm Sci; 2017 Oct; 108():86-92. PubMed ID: 28716757
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Hydrogenated Soybean Phosphatidylcholine Matrices Prepared by Hot Melt Extrusion for Oral Controlled Delivery of Water-Soluble Drugs.
Kolbina M; Schulte A; van Hoogevest P; Körber M; Bodmeier R
AAPS PharmSciTech; 2019 Apr; 20(4):159. PubMed ID: 30968304
[TBL] [Abstract][Full Text] [Related]
3. Denatured Whey Protein Powder as a New Matrix Excipient: Design and Evaluation of Mucoadhesive Tablets for Sustained Drug Release Applications.
Hsein H; Garrait G; Tamani F; Beyssac E; Hoffart V
Pharm Res; 2017 Feb; 34(2):365-377. PubMed ID: 28004316
[TBL] [Abstract][Full Text] [Related]
4. Effect of core size and excipients on the lag time and drug release from a pulsatile drug delivery system.
Efentakis M; Iliopoyloy A; Siamidi A
Drug Dev Ind Pharm; 2011 Jan; 37(1):113-20. PubMed ID: 20615155
[TBL] [Abstract][Full Text] [Related]
5. Interaction between fed gastric media (Ensure Plus®) and different hypromellose based caffeine controlled release tablets: comparison and mechanistic study of caffeine release in fed and fasted media versus water using the USP dissolution apparatus 3.
Franek F; Holm P; Larsen F; Steffansen B
Int J Pharm; 2014 Jan; 461(1-2):419-26. PubMed ID: 24342711
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of drug release from aged prolonged polyethylene oxide tablet matrices: effect of excipient and drug type.
Shojaee S; Kaialy W; Cumming KI; Nokhodchi A
Pharm Dev Technol; 2016 Mar; 21(2):189-95. PubMed ID: 25410967
[TBL] [Abstract][Full Text] [Related]
7. The performance of HPMC matrix tablets using various agglomeration manufacturing processes.
Košir D; Vrečer F
Drug Dev Ind Pharm; 2017 Feb; 43(2):329-337. PubMed ID: 27739880
[TBL] [Abstract][Full Text] [Related]
8. In vitro release testing of matrices based on starch-methyl methacrylate copolymers: effect of tablet crushing force, dissolution medium pH and stirring rate.
Ferrero C; Jiménez-Castellanos MR
Int J Pharm; 2014 Jan; 461(1-2):270-9. PubMed ID: 24333902
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of sustained-release Compritol® 888 ATO matrix mini-tablets.
Roberts M; Vellucci D; Mostafa S; Miolane C; Marchaud D
Drug Dev Ind Pharm; 2012 Sep; 38(9):1068-76. PubMed ID: 22149472
[TBL] [Abstract][Full Text] [Related]
10. Poly vinyl acetate and ammonio methacrylate copolymer as unconventional polymer blends increase the mechanical robustness of HPMC matrix tablets.
Ali R; Dashevsky A; Bodmeier R
Int J Pharm; 2017 Jan; 516(1-2):3-8. PubMed ID: 27818241
[TBL] [Abstract][Full Text] [Related]
11. The effect of powder blend and tablet structure on drug release mechanisms of hydrophobic starch acetate matrix tablets.
van Veen B; Pajander J; Zuurman K; Lappalainen R; Poso A; Frijlink HW; Ketolainen J
Eur J Pharm Biopharm; 2005 Oct; 61(3):149-57. PubMed ID: 16005196
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147
[TBL] [Abstract][Full Text] [Related]
13. Graft copolymers of ethyl methacrylate on waxy maize starch derivatives as novel excipients for matrix tablets: drug release and fronts movement kinetics.
Marinich JA; Ferrero C; Jiménez-Castellanos MR
Eur J Pharm Biopharm; 2012 Apr; 80(3):674-81. PubMed ID: 22210473
[TBL] [Abstract][Full Text] [Related]
14. Incidence of drying on microstructure and drug release profiles from tablets of MCC-lactose-Carbopol and MCC-dicalcium phosphate-Carbopol pellets.
Gómez-Carracedo A; Souto C; Marti Nez-Pacheco R; Concheiro A; Gómez-Amoza JL
Eur J Pharm Biopharm; 2008 Jun; 69(2):675-85. PubMed ID: 18248805
[TBL] [Abstract][Full Text] [Related]
15. The influence of HPMC concentration on release of theophylline or hydrocortisone from extended release mini-tablets.
Mohamed FA; Roberts M; Seton L; Ford JL; Levina M; Rajabi-Siahboomi AR
Drug Dev Ind Pharm; 2013 Aug; 39(8):1167-74. PubMed ID: 22540355
[TBL] [Abstract][Full Text] [Related]
16. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
[TBL] [Abstract][Full Text] [Related]
17. Excipient-excipient interaction in the design of sustained-release theophylline tablets: in vitro and in vivo evaluation.
Bayomi MA; Al-Suwayeh SA; El-Helw AR
Drug Dev Ind Pharm; 2001 Jul; 27(6):499-506. PubMed ID: 11548856
[TBL] [Abstract][Full Text] [Related]
18. Modulation of drug release kinetics from hydroxypropyl methyl cellulose matrix tablets using polyvinyl pyrrolidone.
Hardy IJ; Windberg-Baarup A; Neri C; Byway PV; Booth SW; Fitzpatrick S
Int J Pharm; 2007 Jun; 337(1-2):246-53. PubMed ID: 17306477
[TBL] [Abstract][Full Text] [Related]
19. Limited drug solubility can be decisive even for freely soluble drugs in highly swollen matrix tablets.
Siepmann F; Karrout Y; Gehrke M; Penz FK; Siepmann J
Int J Pharm; 2017 Jun; 526(1-2):280-290. PubMed ID: 28487190
[TBL] [Abstract][Full Text] [Related]
20. The influence of agitation sequence and ionic strength on in vitro drug release from hypromellose (E4M and K4M) ER matrices--the use of the USP III apparatus.
Asare-Addo K; Kaialy W; Levina M; Rajabi-Siahboomi A; Ghori MU; Supuk E; Laity PR; Conway BR; Nokhodchi A
Colloids Surf B Biointerfaces; 2013 Apr; 104():54-60. PubMed ID: 23298588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
